Depressive, inflammatory, and metabolic factors associated with cognitive impairment in patients with epilepsy.

PURPOSE: The purpose of this study was to examine the cognitive function and depressive traits most frequently associated with the clinical assessment of patients with epilepsy and if these clinical parameters are linked to glycolipid levels and inflammatory and apoptotic markers. METHODS: Patients with epilepsy (n = 32) and healthy subjects (n = 41) were recruited to participate in this study. Neuropsychological evaluation was performed in both groups through a battery of cognitive tests. Inflammatory markers, apoptotic factors, and deoxyribonucleic acid (DNA) damage were measured in blood samples. Additionally, the metabolic markers total cholesterol (CHO), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (TG), and glucose (GLU) levels were analyzed. RESULTS: Statistical analyses showed that patients with epilepsy presented decreased scores in memory, attention, language, and executive function tests compared with the control group. Analysis revealed that there was negative correlation in epilepsy for seizure duration vs. oral language (R = -0.4484, p < 0.05) and seizure duration vs. problem solving (executive functions) (R = -0.3995, p < 0.05). This was also observed when comparing depression with temporal-spatial orientation (TSO) (R = -0.39, p < 0.05). Furthermore, we observed a higher depression score in patients with epilepsy than in the healthy ones. Statistical analyses showed higher acetylcholinesterase (AChE) (p < 0.05), interleukin 1ß (IL-1ß, p < 0.001), and tumor necrosis factor-alpha (TNF-α) (p < 0.001) levels compared with those in the control group. Moreover, patients with epilepsy had significantly higher serum levels of caspase 3 (CASP 3) (p < 0.001) and Picogreen (p < 0.001) compared with the control subjects. Regarding the metabolic markers, higher glycolipid levels were observed in the patients with epilepsy (CHO < 0.05*, LDL < 0.0001*, TG < 0.05*, GLU p < 0.05). High-density lipoprotein levels were not significant. The patients with epilepsy had significant correlation when comparing total language with TNF-α (R = -0.4, p < 0.05), praxes with CASP 3 (R = -0.52, p < 0.01), total CHO with total language (R = -0.48, p < 0.05), TG with semantic memory (R = -0.54, p < 0.05), TG with prospective memory (R = -0.2165, p < 0.02), TG with total memory (R = -0.53, p < 0.02), and GLU with total attention (R = -0.62, p < 0.002). CONCLUSION: This study supports the evidence of a distinct neuropsychological profile between patients with epilepsy and healthy subjects. Furthermore, our findings suggest that inflammatory pathway, glycolipid profile, and depressive factors may be associated with cognitive dysfunction in patients with epilepsy.

Protocol for capturing 3D facial meshes for rhinoseptoplasty planning.

OBJECTIVES: To present and execute a protocol for the capture of 3D facial images using photogrammetry through the open access software Blender and its add-on OrtogOnBlender (OOB) and to evaluate the compatibility of the 3D meshes generated with Computed tomography (CT) of the sinuses. METHODS: Individuals >18 years old, candidates for Rhinoseptoplasty in a tertiary hospital, were submitted to a photographic session to perform the standardized protocol. In the session, divided into 3 phases, sequential photos were taken for processing the photogrammetry in the OOB and producing 3D meshes of the face. The photogrammetry reconstructions were compared with the reference mesh of the soft tissue surface of the Sinus CT scan to assess compatibility between them. RESULTS: 21 patients were included, 67% female. 3 photogrammetry meshes and 1 CT reference mesh were generated, which demonstrated matching compatibility, as most of the mean distances between cloud points were <1.48 mm. Phase 3 of the session with the highest number of photos (54.36 ±â€¯15.05) generated the most satisfactory mesh with the best resolution. CONCLUSIONS: The proposed protocol is reproducible and feasible in clinical practice, generated satisfactory 3D meshes of the face, being a potential tool for surgical planning and comparison of results. For the implementation of photogrammetry for use in 3D anthropometry, it is necessary to validate this method. LEVEL OF EVIDENCE: 3: OCEBM Levels of Evidence Working Group.1 "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653.

Protocol for capturing 3D facial meshes for rhinoseptoplasty planning

Abstract Objectives: To present and execute a protocol for the capture of 3D facial images using photogrammetry through the open access software Blender and its add-on OrtogOnBlender (OOB) and to evaluate the compatibility of the 3D meshes generated with Computed tomography (CT) of the sinuses. Methods: Individuals > 18 years old, candidates for Rhinoseptoplasty in a tertiary hospital, were submitted to a photographic session to perform the standardized protocol. In the session, divided into 3 phases, sequential photos were taken for processing the photogrammetry in the OOB and producing 3D meshes of the face. The photogrammetry reconstructions were compared with the reference mesh of the soft tissue surface of the Sinus CT scan to assess compatibility between them. Results: 21 patients were included, 67% female. 3 photogrammetry meshes and 1 CT reference mesh were generated, which demonstrated matching compatibility, as most of the mean distances between cloud points were <1.48mm. Phase 3 of the session with the highest number of photos (54.36 ± 15.05) generated the most satisfactory mesh with the best resolution. Conclusions: The proposed protocol is reproducible and feasible in clinical practice, generated satisfactory 3D meshes of the face, being a potential tool for surgical planning and comparison of results. For the implementation of photogrammetry for use in 3D anthropometry, it is necessary to validate this method. Level of evidence: 3. OCEBM Levels of Evidence Working Group.1 The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653